17th September 2019

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) has significantly increased its tablet manufacturing capabilities following a strategic investment in a new state-of the-art tablet press. This investment will enhance the company’s development and manufacturing capabilities whilst strengthening their ability to support clients’ research, development and clinical manufacturing needs.

The new cutting edge tablet press, a Futorque X- by KG-Pharma is designed specifically to support both R&D studies and production batches.  Indeed the unique features of this machine mean that it equally capable of producing up to 130,000 tablets per hour or supporting DoE and research studies with minimal material and can accommodate multiple tooling formats.

The tablet press is the first in a string of equipment investments being made by the CDMO as a follow-up to receiving MHRA approval for its GMP clinical manufacturing facility.

Paul Kelsall, Director of Clinical Manufacture said: ‘This is an extremely exciting time for the business as we continue to expand on our GMP processing capabilities. We are always looking to increase our capabilities, in our people, plant and processing equipment and this is a huge step forward as we look to support our clients clinical manufacturing requirements.’

Upperton Pharma Solutions develops and produces oral and inhalation drug products for clinical trials and is able to optimise formulation performance through a science-led approach to projects.

Dr Ian Lafferty, Technical Consultant added: ‘The investment in this high specification, versatile instrumented tablet machine provides Upperton Scientists with the equipment to manufacture clinical supplies and will also allow them to generate the data required to gain in-depth understanding and knowledge of process and formulation behaviour during compression that is key to supporting our clients during future scale-up, production and registration stages of their product development.’

The CDMO’s GMP clinical manufacturing capabilities are based at its site in Nottingham, UK and are supported by its materials characterisation, analytical and IP consultancy services.

To read more about Upperton Pharma Solutions’ GMP capabilities click here.

- Ends –

A photograph accompanies this story as appropriate, caption: Upperton Pharma Solutions expand their manufacturing capabilities with a cutting edge tablet press.


Notes to editors:

About Upperton Pharma Solutions: At a time when the global CDMO market place is consolidating, Upperton Pharma Solutions remains as one of the few independent CDMO service providers with a specific focus on developing pharmaceutical dosage forms using its specialised spray drying capabilities. Upperton provides a range of integrated services to the pharmaceutical and biotech sectors around the world. The services include: early feasibility studies, formulation development for both small molecule APIs and Biotherapeutics for a range of final dosage forms and GMP manufacture of materials for Phase I & II clinical trials. Full analytical support, including ICH stability studies, is offered.

The company is a privately-owned organisation that has grown organically over 20 years and now employs 24 highly skilled personnel. Upperton Pharma Solutions has its headquarters in Nottingham, UK.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit upperton.com.


For further information, contact:

Klara Fisken
Business Development Associate
Upperton Pharma Solutions, Albert Einstein Centre, Nottingham Science Park
Nottingham NG7 2TN 
T: +44 (0) 115 855 7050 (Monday to Friday 8.30am – 4.30pm)
E: bd@upperton.com 
W: www.upperton.com